Profitability
Weight: 20%
B
70
- 5yr Avg ROIC 142.0%
- Operating Margin Trend -17845.46 pp/yr
INBX
Inhibrx Biosciences Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 28.7 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
D
35
- 5yr Avg ROE -290.0%
- 5yr Share-Count CAGR -9.3%
Growth Quality
Weight: 15%
F
6
- 5yr Revenue CAGR -36.7%
- Revenue-Growth Years (5) 1/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -25183.0%
- 5yr FCF/NI Conversion -0.12x
Balance Sheet
Weight: 20%
F
22
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -10.48x
- Altman Z-Score 3.64
Stability
Weight: 15%
D-
27
- Negative-Revenue Years (5) 4/5
- Piotroski F-Score 3
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy; 1 trimmed; 1 full exit.
- Holders
- 3
- Avg Δ position
- -10.9%
- New buys
- 1
- Full exits
- 1